INmune Bio Inc.
INMB
$1.23
$0.010.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -25.55% | 8.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.17% | -26.36% | |||
| Operating Income | -6.17% | 26.36% | |||
| Income Before Tax | -2.72% | 18.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -2.72% | 18.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -2.72% | 18.67% | |||
| EBIT | -6.17% | 26.36% | |||
| EBITDA | -6.31% | 27.02% | |||
| EPS Basic | -2.78% | 18.69% | |||
| Normalized Basic EPS | -2.75% | 25.62% | |||
| EPS Diluted | -2.78% | 18.69% | |||
| Normalized Diluted EPS | -2.75% | 25.62% | |||
| Average Basic Shares Outstanding | -0.08% | 0.08% | |||
| Average Diluted Shares Outstanding | -0.08% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||